Evidence map›Paper›PMID 38540725›Full record

ReviewBiomolecules2024

Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones.

Maryam A Salaudeen, Nura Bello, Rabiu N Danraka, Maryam L Ammani

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07670728 (Comparison of Open Vs Closed Kinetic Chain Exercises in Genu Recurvatum Among Stroke Patients), which is not on this map. Cited by 90 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 6 pooled it
48.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07670728 naenrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Comparison of Open Vs Closed Kinetic Chain Exercises in Genu Recurvatum Among Stroke Patients: A Randomized Controlled Trial

TypeinterventionalSponsorDow University of Health SciencesRan2026 to 2026Enrolled60ConditionsCerebrovascular Accident (Stroke), Knee Hyperextension, Genu RecurvatumArmsOpen and closed kinetic chain exercises
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Review
  13. cGAS-STING as a Neuroimmune Traffic Molecule: Unraveling Pathogenic Mechanisms and Therapeutic Potential in Neurological Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Maryam A SalaudeenDivision of Neuroscience, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester M13 9PL, UK.ORCID 0000-0003-4066-7937
Nura BelloDepartment of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria 810107, Nigeria.
Rabiu N DanrakaDepartment of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria 810107, Nigeria.
Maryam L AmmaniDepartment of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.
Ahmadu Bello University · NGKaduna State University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of approved therapies for many diseases are developed to target their underlying pathophysiology. Understanding disease pathophysiology has thus proven vital to the successful development of clinically useful medications. Stroke is generally accepted as the leading cause of adult disability globally and ischemic stroke accounts for the most common form of the two main stroke types. Despite its health and socioeconomic burden, there is still minimal availability of effective pharmacological therapies for its treatment. In this review, we take an in-depth look at the etiology and pathophysiology of ischemic stroke, including molecular and cellular changes. This is followed by a highlight of drugs, cellular therapies, and complementary medicines that are approved or undergoing clinical trials for the treatment and management of ischemic stroke. We also identify unexplored potential targets in stroke pathogenesis that can be exploited to increase the pool of effective anti-stroke and neuroprotective agents through de novo drug development and drug repurposing.

Indexed as

Brain IschemiaIschemic StrokeNeuroprotective AgentsStrokeCell- and Tissue-Based TherapyHumansNeuroprotective Agentscellular therapydrug repurposingischemic strokeneuroinflammationneuroprotectionoxidative stress

Identifiers

PMID38540725
PMCPMC10968326
OpenAlexW4392380338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.